-
1.发明申请公开(公告)号：US20230023075A1
公开(公告)日：2023-01-26
申请号：US17694829
申请日：2022-03-15
申请人： CHEMOCENTRYX, INC.
发明人： James J. CAMPBELL , Zhenhua MIAO , Thomas J. SCHALL , Israel CHARO , Shijie LI , Christine Marie JANSON , Rajinder SINGH , Karen EBSWORTH
IPC分类号： A61K31/536 , A61P35/00 , A61K31/165 , A61K31/357 , A61K45/06
摘要： The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
-
公开(公告)号：US20220280481A1
公开(公告)日：2022-09-08
申请号：US17527939
申请日：2021-11-16
申请人： CHEMOCENTRYX, INC.
发明人： James J. CAMPBELL , Karen EBSWORTH , Antoni KRASINSKI , Venkat Reddy MALI , Jeffrey McMAHON , Rajinder SINGH , Ju YANG , Chao YU , Penglie ZHANG
IPC分类号： A61K31/4035 , A61P29/00 , A61P17/06
摘要： The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:
-
公开(公告)号：US20220226294A1
公开(公告)日：2022-07-21
申请号：US17658494
申请日：2022-04-08
申请人： ChemoCentryx, Inc.
发明人： Zhenhua MIAO , Thomas SCHALL , Rajinder SINGH
IPC分类号： A61K31/444 , A61K35/545 , A61K31/519 , A61K31/4184 , A61K31/403 , A61K31/4422 , A61K31/4178 , A61K39/395 , A61K31/7034 , A61K31/28 , A61K31/4418 , A61K31/137 , A61K31/44 , A61K31/426 , A61P13/12
摘要： A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
-
公开(公告)号：US20210346361A1
公开(公告)日：2021-11-11
申请号：US17128500
申请日：2020-12-21
发明人： James J. CAMPBELL , Rajinder SINGH , Samuel HWANG , Xuesong WU
IPC分类号： A61K31/4433 , C07K16/28 , A61K31/496 , A61P35/00 , A61K39/395
摘要： The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:
-
公开(公告)号：US20210000834A1
公开(公告)日：2021-01-07
申请号：US16990100
申请日：2020-08-11
申请人： CHEMOCENTRYX, INC.
发明人： Zhenhua MIAO , Thomas J. SCHALL , Rajinder SINGH
IPC分类号： A61K31/519 , A61K31/437 , A61K31/422 , A61K31/41 , A61P13/12
摘要： Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.
-
6.发明申请公开(公告)号：US20200297708A1
公开(公告)日：2020-09-24
申请号：US16824585
申请日：2020-03-19
IPC分类号： A61K31/4433 , C07K16/28 , A61K31/496 , A61P35/00 , A61K39/395
摘要： The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.
-
公开(公告)号：US20190144389A1
公开(公告)日：2019-05-16
申请号：US16173914
申请日：2018-10-29
申请人： CHEMOCENTRYX, INC.
发明人： Pingchen FAN , Rebecca M. LUI , Venkat Reddy MALI , Rajinder SINGH , Yibin ZENG , Penglie ZHANG
IPC分类号： C07D211/60 , A61K31/451 , A61K45/06
摘要： Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
-
公开(公告)号：US20230381167A1
公开(公告)日：2023-11-30
申请号：US18305611
申请日：2023-04-24
申请人： CHEMOCENTRYX, INC.
发明人： Rajinder SINGH , Kwok YAU , Yibin ZENG , Penglie ZHANG , Rebecca M. LUI , Antoni KRASINSKI
IPC分类号： A61K31/451 , C07D211/60 , A61K31/675 , A61K39/395
CPC分类号： A61K31/451 , C07D211/60 , C07B2200/13 , A61K39/3955 , A61K31/675
摘要： Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1
Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.-
公开(公告)号：US20230044941A1
公开(公告)日：2023-02-09
申请号：US17576144
申请日：2022-01-14
申请人： CHEMOCENTRYX, INC.
发明人： Pingchen FAN , Christopher LANGE , Venkat Reddy MALI , Darren J. McMURTRIE , Viengkham MALATHONG , Sreenivas PUNNA , Rajinder SINGH , Ju YANG , Yibin ZENG , Penglie ZHANG
IPC分类号： A61K31/4985 , C07D405/12 , C07D471/04 , C07D401/12 , A61K31/506 , C07D403/12
摘要： Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
-
公开(公告)号：US20210276955A1
公开(公告)日：2021-09-09
申请号：US17066986
申请日：2020-10-09
申请人： CHEMOCENTRYX, INC.
发明人： Pingchen FAN , Rebecca M. LUI , Venkat Reddy MALI , Rajinder SINGH , Yibin ZENG , Penglie ZHANG
IPC分类号： C07D211/60 , A61K45/06 , A61K31/451
摘要： Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
55 条记录 (耗时 0.022 秒)
